HE CONTROL OF LINEAGE commitment and differentiation involves the establishment of specific patterns of gene expression by interacting networks of lineage-restricted transcription factor^."^ GATA-1 and GATA-2 have two homologous zinc fingers and bind to (A/T)GATA(A/ G): -' and the stem cell leukemia (SCL; also called tal-l, TCLS) gene encodes a helix-loop-helix motif.'"' These transcription factors are expressed in erythrocytic and megakaryocytic lineages and mast cells, suggesting that they play key roles in controlling hematopoiesis in these lineages.'.'' Because the GATA binding motif is present in the SCL proximal promoter, the SCL gene is a target for GATA-1 It has been demonstrated that the GATA binding motif also is present in the GATA-1 promoter, indicating that GATA-1 expression may be autoregulated or controlled by other GATA transcription factor^.^^-'^ Aberrant expression of the SCL gene plays a key role in hematopoietic neoplasia, as the ectopic expression of the SCL gene as a result of a (1; 14)(p33;qll) translocation has been found in T-cell acute lymphoblastic leukemia (ALL).I4*l5 We have shown that the expression patterns of GATA-1, GATA-2, and the SCL gene may help to define the distinct phenotype of leukemia cells, suggesting that the pattern of expression of transcription factors in leukemic cells correlates with the differentiation level of hematopoietic cells.I6 Although it has been reported recently by other investigators that the expression of these transcription factors can be detected in a subset of human leukemias,".'* the clinical implications of expression of these transcription factors have not been well demonstrated.
In the past, the megakaryocytic nature of hematologic malignancies has been evaluated by assaying for the platelet/ megakaryocyte-associated antigens CD41 and CD42b or for the presence of platelet peroxidase (PPO). '9,20 In analogous studies, erythrocytic invohement has been identified by cytochemical techniques or by the detection of surface antigens BC). SCL gene expression was usually accompanied by GATA-1 expression and was preferentially detected in patients with leukemia exhibiting megakaryocytic or erythrocytic phenotypes, while patients with monocytic leukemia were clustered in the group with no detectable GATA-1 expression. None of the patients with ALL or CML-lymphoid-BC expressed SCL. De novo AML patients with SCL gene expression had a lower complete remission (CR) rate and had a significantly poorer prognosis. Among the patients with AML not expressing SCL, a high percentage of patients with CD7+ AML and CD19' AML had detectable GATA-1, while patients with GATA-1 -negative AML had the best CR rate (87.5%). Our results suggest that the expression pattern of transcription factors reflects the lineage potential of leukemia cells, and GATA-1 and SCL gene expression may have prognostic value for the outcome of patients with AML. for glycophorin A or carbonic anhydolase.21s22 Accordingly, the French-American-British (FAB) criteria have made it possible to determine M6 or M7 in patients with acute myeloid leukemia (AML).23 Moreover, it is possible to determine the involvement of megakaryocyte lineage in chronic myeloid leukemia in blast crisis (CML-BC)."
The aim of this study was to evaluate the clinical implications of the expression of these transcription factors in leukemia. We found that the expression pattern of GATA-1, GATA-2, and SCL gene was associated with the characteristics of certain leukemia cells. Moreover, in patients with de novo AML, the expression pattern of SCL gene and GATA-1 is associated with resistance to chemotherapy, and patients with AML and SCL gene andor GATA-1 expression have a significantly poorer prognosis than those who do not express these genes. We postulated that the expression of these erythrocyte/megakaryocyte-related transcription factors may be important not only for determining the biologic features of leukemia cells, but also for providing important information regarding the clinical management of patients with AML.
Kasumi-l was supplied by Drs H. Asou and N. Kamada (Hiroshima University, Hiroshima, Japan); and the JOSK series was provided by Drs M. Ohta and M. Saito (Jichi Medical School, Tochigi, Japan). The cellular RNA was extracted when the cells were growing logarithmically. The HL-60 cells (2 X 1 0 %~) cultured in growth medium (RPMI 1640 plus 15% FCS) were treated with either 1 mmoU L all-trans-retinoic acid (RA; Sigma, St Louis, MO) or 1 pg/mL of 12-0-tetraadecanoylphorbol-13-acetate (TPA; Sigma) for up to 7 days at 37°C in a humidified atmosphere of 5% CO, in After treatment, the cellular morphology was assessed, and the RNA was extracted using the urea lysis-cesium chloride method." HL-60 cells cultured in the growth medium without inducers served as a control.
Patients and samples. We studied 1 IO consecutive adult patients with leukemia: 76 patients with AML, including 14 patients with post-myelodysplastic syndrome AML (post-MDS AML); 19 with ALL; and 15 with CML-BC. Of the 15 patients with CML-BC, eight had myeloid blast crisis (My-BC), six had lymphoid blast crisis (Lym-BC), and one had an unclassifiable BC. The diagnosis of de novo AML was established based on the FAB l rite ria.'^ AML with trilineage myelodysplasia (AML-TMDS) was identified based on the previously described criteria.** Post-MDS AML was diagnosed as described previously." In this study, we did not encounter patients with T-ALL, and none of our ALL patients had a lp33 chromosome abnormality. The patients with AML were treated with combination chemotherapy, consisting of behenoyl-cytosine arabinose, daunorubicin, 6-mercaptopurine, and prednisolone; some patients with AML-M3 in this study were treated with oral RA (Hoffman La-Roche, Basel, Switzerland). After informed consent was given by the patients, enriched leukemia cells (290%) were obtained by the FicollHypaque density gradient method from heparinized peripheral blood or bone marrow aspirates. Cytogenetic studies were performed routinely after a short-term (less than 48 hours) culture.2Y Bone marrow mononuclear cells from five healthy volunteers were used as a control.
Zmrnunophenotypic study. Cell surface markers were assayed by the modified indirect monoclonal antibody method using a panel of various monoclonal antib~dies.*~~*' The presence of surface antigens associated with plateletslmegakqocytes was determined using TP80 (CD41, GPIIbfiIIa) and AN51 (CD42b, GPIb) monoclonal antibodies. Erythrocyte-related antigens were detected using KOR-E6 (glycophorin A).,' A minimum of 15% blast cells positive for a specific lineage involvement was required for the classification of the lineages.
Expression of transcription factors.
GATA-I, GATA-2, and SCL gene expression were determined by the reverse transcriptasepolymerase chain reaction (RT-PCR).30 Five micrograms of total RNA was mixed with 50 ng of random primer and reverse transcriptase (Takara Shuzo, Kyoto, Japan), and cDNA was synthesized. The cDNA products were amplified with 5 U of Taq polymerase and 50 ng of both a 3"primer and a 5"primer using a Perkin Elmer Cetus Thermal Cycler (Nonvalk, CT). The oligonucleotides and probes used in this study were human GATA-l (sense, TGCTCT- The cycle conditions were as described Briefly, the amplification procedure involved denaturation at 94°C for 30 seconds, annealing for 30 seconds at 58°C for GATA-l and at 63°C for GATA-2, and extension at 72°C for 1 minute during 30 PCR cycles. Cycle conditions for SCL were 2 minutes at 94"C, 2 minutes at 5 5 T , and 2 minutes at 72°C through 35 cycles. Experiments were performed at least three times to confirm their reproducibility. Solution hybridization of 10% of the PCR product was performed with the probe 5' end-labeled with [y"P]-adenosine triphosphate (ATP) by a thermal cycler. Each hybridization sample was run on an 8% polyacrylamide gel, and the gel was autoradiographed at -80°C for 3 hours. We assessed the levels of GATA-I, GATA-2, and SCL gene expression semiquantitatively using densitometric analysis." We used the ratio of GATA-I, GATA-2, or SCL gene expression to that of p-actin in HEL cells as a control. Finally, the ratio in each patient was calculated and compared with those in HEL cells.
Statistical analysis. The statistical analyses were performed in November 1994. We used the Kaplan-Meier method to calculate survival probability.'* We also used the x' test when appropriate."
Hematologic data are expressed as means ? SD. Comparisons of groups were analyzed using the Wilcoxon test. Values of P < .05 were considered significant. Statistical tests were performed using the Statview (Brain Power Inc. Calabasas, CA) software package for the Macintosh (Calabasas) personal computer.
RESULTS
Expression of GATA-I, GATA-2, und SCL gene in leukemia cell lines. To determine the pattern of GATA-l, GATA-2, and SCL gene expression in different cell lineages, we analyzed 17 human leukemia cell lines with various phenotypes using RT-PCR (Fig 1 and Table 1 ). We detected GATA-l , GATA-2, and SCL transcripts in two erythrocytic lines (K562 and HEL) and three megakaryocytic lines (KU8 12, TS9;22, and YS9;22). In contrast, no GATA-I, GATA-2, or SCL products were detected in four monocytic lines (JOSK-S, JOSK-I, JOSK-K, and THP-l), two Blymphocytic lines (B-ALL2 and HAL-Ol), and one Tlymphocytic (MOLT-4) leukemia cell line by RT-PCR. In the myelocytic cell lines, the coexpression of GATA-l and GATA-2 was detected in HL-60 and KG-l cells, while only GATA-2 was detected in ML-l, Eol-3, and Kasumi-l cells; no SCL gene expression was detectable in any of the myelocytic leukemia cell lines ( Table 1) .
To further analyze the expression pattern of these GATA factors during myelocytic and monocytic differentiation, we next examined GATA-1 and GATA-2 expression in HL-60 cells treated with either RA or TPA. After 7 days of treatment with RA, the HL-60 cells exhibited a granulocytic morphology and a slight reduction in GATA-1 expression. By contrast, treatment with TPA (monocytic differentiation) induced a decrease in the level of GATA-l expression at day 3, which became barely detectable on day 7. In contrast, GATA-2 was expressed constitutively in the RA-treated and PA-treated HL-60 cells (Fig 2) .
Expression of transcription factors in leukemia patients. None of the bone marrow specimens obtained from healthy volunteers had detectable levels of SCL by RT-PCR, indicating that the expression of this gene is extremely low in unfractionated normal bone marrow cells. Based on the densitometric analysis, we identified positive levels of transcription factors as greater than 50% of HEL cells. Of the 62 patients with de novo AML, the bone marrow cells from eight (12.9%) expressed SCL, from 30 (48.470) expressed GATA-1, and from 54 (87.1%) expressed GATA-2 ( Table  2 and Fig 3) . All but one of the patients with de novo AML with GATA-l expression also had detectable levels of GATA-2, and all of the specimens from the patients with SCL' AML coexpressed GATA-1. The eight patients with SCL+ AML included one patient each with M6 and M7; two patients had CD41 antigen-positive leukemia cells that also expressed myelocytic antigens andor were positive for myeloperoxidase. Thus, a diagnosis of AML was made in these patients. We identified 22 patients with de novo AML with a GATA-l+SCL-expression pattern; four of the five patients with CD7+ AML and all four patients with CD19' AML with t(8;21)(q22;q22) were included in this group. Six patients with AML-TMDS were identified in the de novo AML group, and three expressed SCL gene, GATA-1, and GATA-2, while two patients coexpressed GATA-l and GATA-2 ( Table 3 ). The 32 patients with de novo AML who did not express GATA-l included all the patients with AML-M3, "4, and "5, except for one patient with M4 (Table 3) . Among these patients, eight had undetectable levels of GATA-2 expression, five had an M5, two had an M2, and one had an M4 morphology.
In contrast, all 14 patients with post-MDS AML expressed GATA-l and GATA-2, while six (42.9%) of these also coexpressed SCL gene (Table 2) . Two patients with GATA-l and SCL gene coexpression also expressed the CD41 antigen, while none of the patients lacking SCL gene expressed any of the megakaryocytic antigens. Cytogenetic analysis demonstrated that none of the patients with de novo AML and post-MDS AML had an abnormality at lp33, where the SCL gene is located.
Most patients (seven of eight) with CML-My-BC coexpressed GATA-1, GATA-2, and SCL gene, and five of these also expressed CD41 antigen, indicating that a high percentage of these patients had megakaryocytic lineage involvement. In contrast, two patients with CML-BC expressed GATA-1 and GATA-2, but not SCL gene (Table 2) ; one each had My-BC and Lym-BC, but neither had any detectable megakaryocytic antigens. None of the patients with ALL or CML-Lym-BC had detectable levels of SCL gene (Table 2) . Among the patients with ALL, two expressed GATA-l and nine expressed GATA-2. In this study, we did not analyze any patients with T-cell ALL, and none of our patients with ALL had a lp33 abnormality.
Outcome of patients with de novo AML expressing transcription factors. In de novo AML, a high percentage of patients with AML without detectable levels of GATA-l obtained a complete remission (CR; 86% v 60% for those with GATA-l' AML), while only 50% of those with SCL' AML obtained a CR. In this study, none of the patients with post-MDS AML, whether they expressed SCL or not, obtained a CR. Next we calculated the survival probability of the patients with de novo AML. First, the patients with de novo AML were divided into two groups according to whether they expressed each transcription factor. The AML patients who expressed GATA-2 had a significantly poorer prognosis than those who did not ( P < .05). The survival probability of those with GATA-I' AML also was significantly poorer than those not expressing GATA-I (Fig 4A; P < .01). Regarding SCL expression, SCL' AML had the poorest prognosis, and most of these patients survived for < 1 year after the diagnosis (Fig 4B) . As the group of patients with GATA-2' AML included those expressing GATA-l and/or SCL, we compared the survival probability of patients with GATA-2'SCL-and those with GATA-2-SCL-AML.
No significant survival difference was observed, suggesting that GATA-2 expression by itself in patients with de novo AML does not affect their survival probability. However, when we compared the survival probability of patients with GATA-l + X L -AML to those with GATA-I 3 C L -AML, a significant difference was observed ( P < .05). This may indicate that GATA-l and SCL gene expression might be independent prognostic factors in de novo AML. SCL gene expression usually was accompanied by GATA-1 expression in the patients with AML. Thus, we attempted to divide the patients with AML into one of three groups according to whether they expressed SCL gene andlor GATA-1 : GATA-1 + X L + AML, GATA-1 + X L -AML, and GATA-1-SCL-AML. As shown in Fig 5, a significant difference in the survival probabilities among these three groups was evident. Patients with SCL+GATA-l+ AML had some distinct clinical and hematologic features, including a low initial white blood cell count ( P < .Ol), more frequent central nervous system involvement during the disease ( P < .05), a high incidence of AML-TMDS (P < .05), and a high incidence of -7ffq-anomaly ( P < .05; Table 3 ).
The CR remission rate of GATA-l-AML was significantly higher (87.5%) than that of GATA-l+ AML, while GATA-1'SCL' AML had a 50.0% CR rate and GATA-1'SCL-AML had a 63.6% CR rate (Table 3) .
DISCUSSION
Among the known transcription factors, both GATA-1 and SCL gene play important roles in the cellular differentiation of erythrocytic and megakaryocytic lineage^,'^-'^ while GATA-2 is considered to maintain and promote the proliferation of early hematopoietic progenitor^.'"^^ The expression of SCL gene was restricted to leukemia cell lines carrying erythrocytic or megakaryocytic phenotypes, in keeping with previous observations>*9 The SCL gene expression always was accompanied by GATA-1 expression in all the erythrocyte/megakaryocyte cell lines, supporting the hypothesis that the SCL gene is a target for GATA-l .'.I" Although the exact control mechanisms of these transcription factors in megakaryocytic or erythrocytic neoplasia are still uncertain, SCL gene expression may be essential in determining the degree of differentiation into neoplastic erythrocytic or megakaryocytic lineages.
Ectopic expression of the SCL gene in T-cell ALL as a result of the translocation (1; 14) has been de~cribed.'~.'~ However, some patients with AML, either those with de novo AML or post-MDS AML, expressed SCL, and four of the eight patients with de novo AML and four of the six patients with post-MDS AML expressing SCL did not express erythrocyte-or megakaryocyte-related antigens (data not shown). The expression of GATA-l and SCL gene was not detected in any samples obtained from normal, nonfractionated bone marrow cells using our RT-PCR conditions. Moreover, there were no significant differences of peripheral and bone marrow blast percentages among patients with AML expressing GATA-l, GATA-2, or SCL gene (Table 3) , and we used enriched leukemia cells. Therefore, the current results likely represent characteristics of leukemia cells rather than a contaminating erythroid component or detection of heterogeneous cell populations that expressed each transcription factor. Although we did not perform a PP0 study in all of these patients, the SCL gene expression in some patients with de novo AML patients may represent the ability to differentiate into an erythrocyte or megakaryocyte lineage, rather than being related to ectopic expression, because none of our patients with AML had any apparent chromosomal changes in the lp33 region. No previous reports dealing with SCL gene expression in freshly obtained leukemia cells have appeared; thus, confirmation of our results is required. Most of our patients with de novo AML with M4 or M5 morphologies did not express GATA-l. In contrast, Guerrasio et all8 nervous system leukemia during the course of the disease.
t P < .05 V GATA-1+SCL-PIUS GATA-I-SCL-.
* P < .05 vGATA-l+SCL+ PIUS GATA-l+SCL-.
have detected GATA-1 mRNA in four of six patients with AML-M4, but in none of those with AML-MS. However, none of the monocytic leukemia cell lines examined expressed GATA-l or GATA-2. In patients with de novo AML, SCL expression was an indicator of a poor prognosis. This may be due to the expression of erythrocytelmegakaryocyte-related antigens, because patients with AML-M7 have a significantly poorer prognosis than do those with other forms of AML.4' GATA-1 expression in patients with de novo AML also was associated with a poorer prognosis. Approximately 6 4 % of the patients with de novo AML with a GATA-1'SCL-expression pattern obtained a CR. In contrast, the patients with de novo AML without GATA-1 expression had an 87.5% CR rate, and they had a favorable survival probability. All three patients with t(15;17)(q22;q21) and all four with inv(16)(p13q22) were included in the GATA-1-AML group (Table 3) . It is known that patients with AML with t(15;17)(q22;q21) and inv(16)(p13q22) abnormalities have high CR races and have favorable prognoses. However, we did not find any significant differences in survival probabilities whether or not patients had these specific cytogenetic abnormalities in the group of GATA-1-AML. This indicates that the absence of GATA-l expression may be an independent factor that predicts a favorable prognosis for patients with de novo AML. It has been reported that patients with AML-TMDS have a low CR rate and a poor Therefore, a relatively poor prognosis for patients with GATA-l+ AML may (Table 3) , a greater number of patients must be studied before any conclusion can be made regarding the significance of these differences.
In conclusion, w e analyzed the expression pattern of the erythrocytelmegakaryocyte-related transcription factors GATA-1, GATA-2, and SCL gene in various human leukemia cells. Although this study was performed using a relatively small number of patients, we demonstrated that the SCL gene and GATA-1 expression patterns may affect the prognosis of adult patients with AML. 
